[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-cell-carcinoma-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-cell-carcinoma-metastatic":217},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,73,113,145,172,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100413113","tdm-for-optimized-outcome-in-patients-with-mrcc-100413113",false,"NCT04659343","TDM for Optimized Outcome in Patients With mRCC.","Therapeutic Drug Monitoring for Optimized Outcome in Patients With Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Patients in Denmark with medically treated metastatic renal cell carcinoma.\n\nExclusion Criteria:\n\n* No written informed consent.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients.\n\nFurthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.",[24,25,26,27,28],"Kidney Cancer","Renal Cell Carcinoma Metastatic","Drug Toxicity","Drug Side Effect","Drug Mechanism","RECRUITING","2026-04-28",{"date":32,"type":33},"2026-05-04","ACTUAL",{"date":35,"type":33},"2020-11-01",{"date":37,"type":20},"2029-08-31",{"name":39,"class":40},"Niels Fristrup","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100360779","deferred-cytoreductive-nephrectomy-in-synchronous-metastatic-renal-cell-carcinoma-the-nordic-sun-trial-100360779","NCT03977571","Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial","Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: a Trial Evaluating the Impact of Surgery or No Surgery. The NORDIC-SUN-Trial","NORDIC-SUN","Inclusion Criteria:\n\n1. Signed written informed consent obtained prior to any study specific procedures.\n2. Patient must be willing and able to comply with the protocol.\n3. Age ≥18.\n4. Core needle biopsy proven metastatic renal cell carcinoma - all histologic subtypes acceptable.\n5. Synchronous metastatic renal cell carcinoma with the primary tumor present in the kidney.\n6. Measurable disease as per RECIST v 1.1\n7. Patients for which Nivolumab\u002FIpilimumab or a TKI\u002FIO-combination is considered indicated according to the recommendations by the European Medicines Agency and the national health authorities of participating countries. The prescription of nivolumab\u002Fipilimumab or a TKI\u002FIO-combination in the circumstances of the study is considered as a standard treatment.\n8. Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.\n9. Fertile women of childbearing potential (\\\u003C2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).\n10. Karnofsky Performance status ≥70\n11. Life expectancy of greater than 4 months.\n12. The required laboratory values are as follows:\n\n    * Adequate bone marrow function (Leucocytes \\> 3.0 x 109\u002Fl, platelets \\> 100 x 109\u002Fl, hemoglobin \\> 6.0 mmol\u002Fl or \\> 10.0 g\u002FdL.)\n    * International normalized ratio (INR) ≤ 1.2 x upper limit of normal (ULN)\n    * Adequate hepatic function (bilirubin ≤ 1.5 x ULN, ALAT ≤ 2.5 x ULN or ≤ 5 x ULN if liver lesions)\n    * Adequate kidney function (eGFR \\> 35 mL\u002Fmin)\n\nExclusion Criteria:\n\n1. Prior systemic treatment for mRCC\n2. Other cancer within 3 years (except in situ basal cell carcinoma and localised prostate cancer with undetectable PSA).\n3. Major surgical procedure, open surgical biopsy, or significant traumatic injury within 28 days prior to enrollment\n4. Clinically significant (i.e active) cardiovascular disease for example cerebrovascular accidents (\\\u003C 6 months before inclusion), myocardial infarction (\\\u003C 6 months before inclusion), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure.\n5. No symptomatic brain metastasis requiring systemic corticosteroids (\\> 10 mg daily prednisone equivalent)\n6. Recent (within the 30 days prior to inclusion) treatment with another investigational drug or participation in another investigational study.\n7. Any active or recent history of a known or suspected autoimmune disease or recent history of a condition that require systemic corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications, excluding inhaled steroids and topical steroids. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, psoriasis not requiring systemic treatment are permitted to enroll.\n8. Known hypersensitivity to monoclonal antibodies.\n9. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n10. Any positive test for hepatitis B- or C-Virus indicating acute or chronic infection.\n11. Oral or i.v. antibiotics administered 14 days prior to initiation of systemic therapy.",{"count":51,"type":20},400,"INTERVENTIONAL",[54],"NA","BACKGROUND: For synchronous metastatic renal cell carcinoma (RCC), surgical resection of the primary tumor in the presence of distant metastases has been the standard of therapy for select patients followed by systemic therapy. In the era of TKIs two randomized trials, CARMENA and SURTIME, have questioned the role and timing of surgery in these patients, results point towards no surgery or a deferred approach.\n\nRATIONALE: The antitumor activity of immune checkpoint blockage (ICB) is more potent than other therapy in mRCC. The deferred cytoreductive nephrectomy approach ensures systemic therapy for all patients, avoid systemic treatment delay, and spare surgery in patients with progressive tumors. Current data only point towards a survival benefit for cytoreductive nephrectomy in intermediate risk patients, but not in poor risk patients\n\nHYPOTHESIS: Deferred cytoreductive nephrectomy after initial nivolumab combined with ipilimumab or a TKI\u002FIO-combination will improve OS in patients with synchronous metastatic RCC and ≤3 IMDC risk features\n\nThis is an open, randomized, multicenter comparison trial, designed to evaluate the effect of deferred cytoreductive nephrectomy compared with no surgery following initial nivolumab combined with ipilimumab or a TKI-combination, in mRCC patients with IMDC intermediate and poor risk.",[24,25,57],"Synchronous Neoplasm",[59,60,61,62,63,64,65],"Cytoreduction Surgical Procedures","Nephrectomy","Ipilimumab","Nivolumab","Laboratory biomarker analysis","Gene Expression","Liquid Biopsy",{"date":32,"type":33},{"date":68,"type":33},"2020-07-06",{"date":70,"type":20},"2031-12-01",{"name":39,"class":40},6,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":52,"phases":83,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100615404","phase-1-a-phase-1b2-study-of-the-safety-and-efficacy-of-the-monoclonal-antibody-om-rca-01-in-patients-with-metastatic-tumors-expressing-fibroblast-growth-factor-receptor-1-100615404","NCT07292168","A Phase 1b\u002F2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1","A Phase 1b\u002F2 Study Evaluating the Safety and Preliminary Efficacy of OM-RCA-01, an Anti-FGFR1 Monoclonal Antibody, in Patients With Metastatic Cancers Expressing FGFR1.","TAGNOT","Inclusion Criteria:\n\n1. Signed and dated Informed Consent Form confirming voluntary participation in the study.\n2. Age ≥ 18 years at the time of consent.\n3. Body weight ≥ 50 kg.\n4. Histologically confirmed metastatic solid tumors:\n\n   1. clear-cell renal cell carcinoma;\n   2. non-small cell lung cancer (adenocarcinoma or squamous cell cancer without EGFR and ALK mutations);\n   3. prostate cancer (castration-resistant adenocarcinoma);\n   4. breast cancer (adenocarcinoma with specified status for estrogen receptors, progesterone receptors, HER2);\n   5. head and neck tumors (squamous carcinoma, salivary gland cancer).\n5. Immunohistochemical expression of FGFR1 of 2+ or higher.\n6. Documented disease progression after at least two lines of standard therapy, or lack of available or feasible alternative standard treatment options for any reason.\n7. Presence of at least one measurable lesion according to RECIST 1.1 criteria.\n8. Availability of formalin-fixed and paraffin-embedded tumor tissue samples for biomarker analysis.\n9. ECOG performance status 0 or 1.\n10. Adequate organ function, confirmed by laboratory test results obtained within 7 days prior to Cycle 1 Day 1, meeting the following parameters:\n\n    * Hemoglobin level ≥ 90 g\u002FL\n    * Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL\n    * Platelet count ≥ 100 × 10⁹\u002FL\n    * Serum creatinine level ≤ 1.5 × upper limit of normal (ULN)\n    * Glomerular Filtration Rate (GFR) ≥ 30 mL\u002Fmin\n    * AST and ALT ≤ 3 × ULN (≤ 5 × ULN in patients with liver metastases)\n    * Serum phosphorus within normal limits (≥ lower limit of normal and ≤ upper limit of normal)\n    * Serum calcium ≥ lower limit of normal\n    * Serum potassium ≥ lower limit of normal (note: use of medications to increase potassium during screening is permitted)\n11. Life expectancy of more than 12 weeks.\n12. Absence of any psychological, familial, social or geographical circumstances that could potentially serve as an obstacle to the fulfillment of the study protocol and follow-up procedures according to the prescribed schedule and the ability of the study participant to follow the requirements of the protocol; these circumstances should be discussed with the patient before inclusion in the study.\n13. Women capable of childbearing must be using an effective method of contraception.\n\nExclusion Criteria:\n\n1. Participation in another clinical trial or concomitant treatment with any investigational drug, or administration of any investigational anticancer therapy within 28 days prior to inclusion in this study.\n2. Presence of central nervous system (CNS) metastases and\u002For medullary carcinomatosis at the time of inclusion.\n\n   Exception: Patients with CNS metastases who have received therapy may participate if they have been clinically stable for at least 1 month prior to enrollment, defined by:\n   * No evidence of new or progressive CNS metastases\n   * No ongoing steroid therapy\n   * Stable mental status sufficient to provide informed consent\n3. History of or current evidence of any condition, therapy, or laboratory abnormality that could:\n\n   * Limit interpretation of study results,\n   * Prevent completion of the study protocol, or\n   * Pose a risk to patient safety or well-being. This includes any serious or unstable general medical, psychiatric, or other conditions potentially jeopardizing safety, informed consent, or compliance.\n4. Any second malignancy within the previous 5 years, except for adequately treated cervical carcinoma in situ, squamous cell carcinoma of the skin, or basal cell carcinoma of the skin with limited growth, provided these are well controlled.\n5. Known regular use of illicit substances or recreational drugs, or a history of drug abuse or alcoholism within the past year.\n6. Plans to conceive during the study period, current pregnancy, or lactation.\n7. Known HIV-positive status.\n8. Known active hepatitis B or C infection.\n9. Evidence of active bleeding or hemorrhagic diathesis.\n10. Radiation therapy within 14 days prior to inclusion.\n11. Receipt of any anti-tumor treatments including:\n\n    * Surgery or tumor embolization within 14 days prior to the first OM-RCA-01 dose, or\n    * Chemotherapy, immunotherapy, biological therapy, investigational therapy, or endocrine therapy (except ongoing androgen deprivation therapy for prostate cancer) within 14 days or within two half-lives of the drug (whichever is longer) prior to the first OM-RCA-01 dose.\n12. Prior treatment with any FGFR-inhibiting or FGFR-blocking agents.",{"count":82,"type":20},58,[84,85],"PHASE1","PHASE2","One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family.\n\nThe goal of this clinical trial is to learn if monoclonal anti-FGFR1 antibody (OM-RCA-01) works to treat metastatic cancers expressing FGFR1. It will also learn about the safety of drug OM-RCA-01. The main questions it aims to answer are:\n\n1. What medical problems do participants have when receiving drug OM-RCA-01?\n2. What dose of the drug should patients receive in the next studies?\n3. Does tumor growth slow down in patients receiving OM-RCA-01?\n\nAll patients in this study will receive the antibody treatment. The drug will be given through a vein (by IV infusion) every two weeks, for as long as the disease remains under control and the treatment is well tolerated.",[25,88,89,90,91],"Prostate Cancer Metastatic","Non-small Cell Lung Cancer Metastatic","Breast Cancer Metastatic","Head & Neck Cancer",[93,94,95,96,97,98,99,100,101,102],"metastatic cancer","resistance","monoclonal antibody","fibroblast growth factor receptor 1","OM-RCA-01","kidney cancer","prostate cancer","head & neck cancer","lung cancer","breast cancer","2026-01-20",{"date":105,"type":33},"2026-01-21",{"date":107,"type":33},"2025-12-02",{"date":109,"type":20},"2027-01-01",{"name":111,"class":40},"Kidney Cancer Research Bureau",5,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":52,"phases":123,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100571912","phase-3-systemic-therapy-alone-or-with-stereotactic-body-radiotherapy-for-oligometastatic-kidney-cancer-stroker-study-100571912","NCT06726421","Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","Systemic Therapy Combined With Radiotherapy Versus Systemic Therapy Alone for Oligometastatic Kidney CancER (STROKER): A Multicenter, Randomized Controlled Phase III Trial","STROKER","Inclusion Criteria:\n\n* Pathologically confirmed diagnosis of renal cell carcinoma of any histology\n* Age ≥ 18 years.\n* ECOG performance status of 0-2.\n* Imaging suggests the presence of distant metastases, with no more than 5 metastatic lesions according to RECIST 1.1 criteria and MDA standards.\n* The patient has received local therapy to primary site, including surgery, stereotactic radiotherapy, or ablation.\n* The patient has received no more than 2 lines of systemic therapy.\n* No significant impairment of major organ function:\n\nHemoglobin (HB) ≥ 80 g\u002FL Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL Platelets (PLT) ≥ 75 × 10⁹\u002FL Serum total bilirubin ≤ 1.5 × ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN\n\nExclusion Criteria:\n\n* Presence of intracranial metastases.\n* Target lesions have previously received high-dose irradiation with .\n* Target lesions are unsuitable for radiation therapy judged by treating radiation oncologist (e.g., lesions invading the gastrointestinal tract or penetrating the bronchus).\n* Uncontrollable metastatic pleural effusion or ascites.\n* Presence of other malignancies that have not been cured.\n* History of significant psychiatric disorders that impede understanding of informed consent and compliance with the study protocol.\n* Presence of other serious illnesses that may pose significant risks or affect radiation therapy.\n* Women who are pregnant, breastfeeding, or with plans for childbearing during the study.\n* Any other reasons deemed by the investigator to make the subject unsuitable for participation in the study.",{"count":122,"type":20},252,[124],"PHASE3","This phase III randomized controlled trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) in oligometastatic renal cell carcinoma. The study aims to determine if the addition of SBRT to standard systemic therapy prolong survival compared to the standard systemic therapy alone. In addition, the study will explore the impact of this combined modality therapy on patients' toxicity and quality of life. The researchers will compare SBRT plus standard systemic therapy to standard systemic therapy alone, which is targeted agents and immunotherapy in this case, to determine if SBRT could prolong survival.",[127,128,25],"Renal Cell Carcinoma (Kidney Cancer)","Kidney Cancer Metastatic",[130,131,132,133,134],"radiotherapy","SBRT","SABR","oligometastatic","oligometastasis","2026-01-14",{"date":137,"type":33},"2026-01-15",{"date":139,"type":33},"2024-09-18",{"date":141,"type":20},"2033-09-30",{"name":143,"class":40},"Sun Yat-sen University",9,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":52,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":41},"100592610","partial-volume-high-dose-irradiation-in-renal-cell-carcinoma-for-intra-tumoural-control-alongside-current-management-100592610","NCT06995664","Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management","Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management - a Randomised Feasibility Study","VIRTUAL","Inclusion Criteria:\n\n* Histologically confirmed renal cell carcinoma (RCC) (histological confirmation of metastasis not required) or clinically consistent with RCC as per multidisciplinary team (MDT) diagnosis.\n* Not suitable for surgical resection, metastasectomy or ablative therapy due to tumour or patient factors\n* All extracranial sites which clinically require radiotherapy (as per clinician discretion)\n* Age ≥18 years\n* Karnofsky Performance Status (KPS) ≥50\n* Adequate baseline organ function applicable to site-of irradiation\n* Haemaglobin ≥90g\u002Fdl\n* Platelets ≥50\n* Bilirubin \\\u003C3x ULN\n* INR \\\u003C1.4 or correctable with vitamin K\n* AST or ALT \\\u003C5x normal range\n* Creatinine \\\u003C200umol\u002FL (or established on dialysis). Note patients on dialysis are unable to have dynamic contrast enhanced MRI.\n* The use of concurrent systemic therapy is acceptable\n* Ability of the research subject to understand and the willingness to sign a written informed consent document\n* Able to undergo all mandated staging and follow-up investigations\n* Negative pregnancy test (for women of childbearing potential)\n\nExclusion Criteria:\n\n* Expected prognosis \\\u003C6 months\n* Uncontrolled intracranial metastases\n* Previous radiotherapy, such that the delivery of further radiotherapy is not feasible\n* Unable to have necessary radiotherapy planning, radiotherapy related investigations\u002Ffiducials (if required)\n* Co-morbidities or any psychological, familial, sociological or geographical condition which may preclude ability to undergo\u002Fattend investigations, treatment or follow-up\n* Other active primary cancer\n* Pregnant or lactating\n* Requiring ongoing treatment with a concomitant medication, which is contraindicated alongside radiotherapy (e.g. methotrexate)",{"count":154,"type":20},24,[54],"Prospective, randomised, feasibility study of patients with localised or metastatic renal cell carcinoma (RCC) comparing standard palliative dose radiotherapy to a high-dose hypofractionated regime.\n\nPrimary aim\n\n• To demonstrate feasibility of a randomised study comparing high-dose hypofractionated radiotherapy versus standard palliative dose radiotherapy in localised or metastatic renal cell carcinoma The aim is to recruit a minimum of 24 patients; 12 to the control arm and 12 to the high-dose regime.\n\n2 treatment arms, no placebo:\n\n* Control arm - standard palliative-dose radiotherapy, 30Gy in 10 fractions in 3Gy per fraction over 2 weeks\n* High-dose arm - high-dose radiotherapy, 30Gy in 5 fractions in 6Gy per fraction on alternate days\u002F2-3 fractions a week over 2 weeks",[158,25],"Renal Cell Carcinoma",[160,161,130,162],"standard palliative dose radiotherapy","high-dose hypofractionated radiotherapy","unblinded","2025-05-21",{"date":165,"type":33},"2025-05-29",{"date":167,"type":33},"2023-03-27",{"date":169,"type":20},"2026-05",{"name":171,"class":40},"Royal Marsden NHS Foundation Trust",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":41},"100481409","a-prospective-study-to-evaluate-the-implementation-of-shared-decision-making-strategy-for-renal-cell-cancer-rcc-100481409","NCT05548621","A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)","SDM-RCC","Inclusion Criteria:\n\n* Patients clinically diagnosed with RCC\n* Patients facing a decision which is addressed in the decision aids (T1 tumor or metastatic disease)\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients who are not able to fill in a questionnaire or undergo an interview individually",{"count":180,"type":20},180,"The aim of this study is to evaluate the effect of two decision aids for renal cell carcinoma (RCC) on the decision-making process and the quality of the decision.",[158,25],[184,185],"decision aid","renal cell carcinoma","2025-05-12",{"date":188,"type":33},"2025-05-15",{"date":190,"type":33},"2022-11-24",{"date":192,"type":20},"2025-12",{"name":194,"class":40},"St. Antonius Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":52,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":41},"100540777","phase-1-a-study-of-jmkx003948-tablets-in-patients-with-renal-cell-carcinoma-100540777","NCT06321250","A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma","An Open-label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX003948 Tablets in Patients With Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Has the ability to understand and willingness to sign a written informed consent form.\n2. Male or female from 18 years of age or older.\n3. Histologically confirmed locally advanced or metastasis clear cell renal cell carcinoma.\n4. Has at least one measurable lesion per RECIST v1.1.\n5. Has a life expectancy of ≥ 12 weeks.\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Patients with known active CNS metastases and\u002For cancerous meningitis.\n2. Has received any type of systemic anticancer monoclonal antibodies or other immunosuppressants within 4 weeks prior to the first dose. Has received prior chemotherapy, targeted therapy, or other investigational therapy within 2 weeks prior to the first dose.\n3. Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy.\n4. Has impaired heart function,or clinically significant cerebrovascular and cardiovascular disease.\n5. Subjects with dysphagia or known drug absorption disorders.\n6. Has a history of any other malignancy within 5 years.\n7. Has severe oncological complications.\n8. Is currently participating in other clinical studies.\n9. Subjects with be unsuitable for participation in the trial evaluated by investigator.",{"count":203,"type":20},80,[84],"This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.",[25],"2024-07-06",{"date":209,"type":33},"2024-07-09",{"date":211,"type":33},"2024-03-14",{"date":213,"type":20},"2027-04-30",{"name":215,"class":216},"Jemincare","INDUSTRY","Renal Cell Carcinoma, Metastatic"]